- May 7
Previewing the 2024 ASGCT Annual Meeting in Baltimore with gene editing expert TJ Cradick
- May 6
A computational biologist and assistant professor at Philadelphia’s Wistar Institute on positives and potential negatives of AI’s emergence to the forefront of life sciences
- May 6
Founder Mark Kotter describes the science that has enabled bit.bio to design and manufacture virtually any cell type and characteristic from iPSCs
- May 6
Ochre Bio CEO Jack O'Meara discusses his company's focus on liver diseases and its recent Boehringer Ingelheim partnership
- May 6
How Cambridge Innovation Capital has become a preeminent investment firm in Cambridge life sciences, and also a significant attractor of outside capital to Cambridge
- May 6
A pioneer in fragment based drug discovery, Harren Jhoti describes how Astex Pharma has contributed to three now approved medicines since its founding in Cambridge in 1999